David Lund, Ph.D.

David Lund

David Lund, Ph.D., is the Vice President, Intellectual Property at Neogene Therapeutics. Before coming to Neogene, Dr. Lund served most recently as Senior IP Counsel at Agenus, where his responsibilities included managing IP issues for Agenus’ affiliate AgenTus in addition to early stage and near-commercial antibody programs of Agenus. Prior to that, Dr. Lund was […]

Kanti Thirumoorthy, Ph.D.

Kanti Thirumoorthy

Dr. Thirumoorthy is the Senior Vice President of Technical Operations at Neogene Therapeutics. She has 19 years of experience in the pharmaceutical industry, including in cell therapies, with expertise in technical operations, chemistry, Manufacturing and Control (CMC), quality control and quality assurance/compliance. Before joining Neogene, she spent six years at Kite Pharma, where she most […]

Arianne Perez Garcia, Ph.D.

Arianne Perez

Dr. Perez Garcia is the Vice President of Translational Sciences at Neogene Therapeutics. She has more than 16 years of combined academic and biopharma industry experience in cancer immunology and immunotherapy research supporting preclinical projects for engineered T cell therapies in oncology. Before joining Neogene, she spent nearly seven years at Kite Pharma, where she […]

Gavin M. Bendle, Ph.D.

Dr. Gavin M. Bendle is the Senior Vice President of Research and Development at Neogene Therapeutics. He has been actively engaged in the field of adoptive T cell therapy of cancer for over 17 years and has co-authored numerous publications on this subject. Before joining Neogene, Dr. Bendle was a Senior Director of Cell Therapy […]

Carsten Linnemann, Ph.D.

Carsten Linneman

Carsten Linnemann, Ph.D., is the President, Chief Executive Officer, and a Co-Founder of Neogene Therapeutics. Before Neogene, Dr. Linnemann served as Associate Director, Next Generation T Cell Therapies and Managing Director of Kite Pharma EU B.V. He has co-founded several biotech companies, including T-Cell Factory B.V. (acquired by Kite Pharma, Inc. in 2015). He has […]